Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.

doi:10.1016/0049-3848(90)90109-p

Back to search

Article

Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.

Thrombosis research - 15 Nov 1990

Suehiro K, Miyata T, Takeya H, Takamatsu J, Saito H, Murakawa M, Okamura T, Niho Y, Iwanaga S

Abstract excerpt

Factor IX Nagoya 3 (IX Nagoya 3) is a natural mutant of factor IX recognized in a patient with moderately severe hemophilia B. The patient had 0.60 units/ml of factor IX antigen and 2-5% of clotting activity. IX Nagoya 3 was purified from the patient's plasma by immunoaffinity chromatography with...

Topics

Amino Acid Sequence
Calcium
Factor IX
Factor XIa
Humans
In Vitro Techniques
Molecular Sequence Data
Mutation

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.